UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.